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ABSTRACT
Introduction Environmental enteropathy (EE) is 
suspected to be a cause of growth faltering in children 
with sustained exposure to enteric pathogens, typically 
in resource- limited settings. A major hindrance to EE 
research is the lack of sensitive, non- invasive biomarkers. 
Current biomarkers measure intestinal permeability 
and inflammation, but not the functional capacity of the 
gut. Australian researchers have demonstrated proof of 
concept for an EE breath test based on using naturally 13C- 
enriched sucrose, derived from maize, to assay intestinal 
sucrase activity, a digestive enzyme that is impaired in 
villus blunting. Here, we describe a coordinated research 
project to optimise, validate and evaluate the usability of a 
breath test protocol based on highly enriched 13C- sucrose 
to quantify physiological dysfunction in EE in relevant 
target populations.
Methods and analysis We use the 13C- sucrose breath 
test (13C- SBT) to evaluate intestinal sucrase activity in two 
phases. First, an optimisation and validation phase will 
(1) confirm that a 13C- SBT using highly enriched sucrose 
tracers reports similar information to the naturally enriched 
13C- SBT; (2) examine the dose–response relationship 
of the test to an intestinal sucrase inhibitor; (3) validate 
the 13C- SBT in paediatric coeliac disease (4) validate the 
highly enriched 13C- SBT against EE defined by biopsy in 
adults and (5) validate the 13C- SBT against EE defined by 
the urinary lactulose:rhamnose ratio (LR) among children 
in Peru. Second, a cross- sectional study will be conducted 
in six resource- limited countries (Bangladesh, India, 
Jamaica, Kenya, Peru and Zambia) to test the usability of 
the optimised 13C- SBT to assess EE among 600 children 
aged 12–15 months old.
Ethics and dissemination Ethical approval will be 
obtained from each participating study site. By working 
as a consortium, the test, if shown to be informative of 
EE, will demonstrate strong evidence for utility across 
diverse, low- income and middle- income country paediatric 
populations.
Trial registration number NCT04109352; Pre- results.
INTRODUCTION
Retarded linear growth, resulting in stunting 
(length- for- age or height- for- age below 2 
Z- scores of WHO growth standards), affects 
Strengths and limitations of this study
 ► A validated non- invasive 13C- sucrose breath test 
(13C- SBT) would overcome a major current limita-
tion of environmental enteropathy (EE) research 
by providing an assay that explicitly measures the 
function of the intestinal epithelium to digest and 
absorb nutrients.
 ► The test is supported by early proof- of- concept data 
from a study that used a naturally enriched 13C- SBT 
to characterise intestinal function in children with 
possible EE. However, this test is limited by low sig-
nal to noise in the breath 13CO2 signal.
 ► This coordinated research project design includes 
sequential validation and feasibility studies in both 
adult and paediatric populations.
 ► The large network permits validation in multiple geo-
graphic sites, in Southeast Asia (India, Bangladesh), 
Africa (Zambia, Kenya), Latin America (Peru) and the 
Caribbean (Jamaica).
 ► If the 13C- SBT provides a functional readout related 
to EE, it would facilitate the validation and use of test 
substrates using a similar approach for the assess-
ment of EE, with broad field applicability.
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23% of children under 5 years, most of whom live in 
low- income and middle- income countries.1 Stunting is 
associated with increased child morbidity and mortality,2 
poorer cognitive development,3 school performance4–6 
and lower adult wages,7 and, for girls, poorer maternal 
health outcomes.8
The aetiology of stunting is multifactorial, including 
generational and prenatal factors.9 10 Postnatal exposures 
also play a major role. Most postnatal growth faltering 
occurs around 6–18 months of age,11 an age when the 
energy and nutrient requirements for rapid growth are 
high. For children living in communities without access 
to improved water and sanitation, this period is also asso-
ciated with intense exposure to enteric pathogens, while 
protection from breast feeding and maternal antibodies 
begin to wane. Although driven by underlying environ-
mental, social and familial factors, inadequate diet and 
exposure to pathogens are the major, proximal causes of 
infant growth faltering.10 However, nutritional interven-
tions lead to only small to moderate improvements in 
growth,12 and two recent, large studies to reduce enteric 
infection found no impact of water and sanitation inter-
ventions on child growth, or evidence of synergy between 
water, sanitation and hygiene (WASH) interventions and 
nutritional interventions.13–15 These findings reinforce 
the need to better understand the biological basis of 
stunting.
Since the 1960s, it has been noted that adults and chil-
dren living without access to improved water and sanita-
tion have altered small intestinal morphology,16 including 
diffuse, upper small bowel villous atrophy accompanied 
by evidence of barrier disruption and inflammation.17 18 
This condition is linked to chronic bacterial translocation 
leading to systemic inflammation, and T- cell- mediated 
hyperstimulation of the mucosal immune system, nega-
tively impacting nutrient absorption and utilisation.19 20 
This increases the risk of nutrient deficiency, which may 
in turn further impair gut immune responses.10 It is theo-
rised that this condition, successively termed, ‘tropical 
enteropathy’, ‘environmental enteropathy (EE)’ and 
most recently, ‘environmental enteric dysfunction’,21 is 
a major contributing cause of the failure of both nutri-
tional, and water and sanitation- oriented interventions, 
to significantly improve child growth.
Despite the potential significance of EE to child nutri-
tion and health, there is a lack of simple diagnostic tech-
niques to identify or classify the condition.22 A primary 
challenge has been that morphological confirmation of 
EE requires intestinal biopsy. In the absence of this, EE 
is studied using non- invasive biomarkers of gut function. 
The most common approaches to determining EE use the 
dual- sugar lactulose: mannitol or LR ratio,23 or composite 
scores based on multiple biomarkers intended to capture 
multiple domains of gut dysfunction.24 25 However, dual- 
sugar tests, although non- invasive, are time- consuming to 
administer, vary greatly in protocol details, and concerns 
have been raised about interplatform consistency.26 The 
relationship of alternative biomarkers to EE, and to each 
other, is also not well understood.27 Candidate biomarkers 
to define EE have frequently been ‘borrowed’ from the 
field of paediatric gastroenterology, and specifically, from 
the study of coeliac disease, which produces an enterop-
athy regarded as having histopathological and immune 
similarities to EE.28 However, in many cases, there is a 
lack of descriptive data bridging biomarker performance 
between children with severe paediatric gastrointestinal 
disease, well- child controls in high- income countries 
and children from high- risk EE settings. This dimin-
ishes the interpretability of these tests. For example, 
faecal biomarkers of intestinal inflammation, myelop-
eroxidase and alpha-1- antitrypsin, have been proposed 
for EE, but reference values for healthy, well- growing 
children remain limited.25 Despite these limitations, 
the shift in nomenclature from ‘EE’ to ‘environmental 
enteric dysfunction’, first proposed by Keusch et al21 and 
now adopted by a significant proportion of the research 
community, emerged from the viewpoint that, given the 
infeasibility of biopsy- confirmed ‘enteropathy’, diagnosis 
should be based instead on ‘functional’ biomarkers, as 
well as on functional consequences for child growth and 
development.
Most existing EE biomarkers reflect processes of intes-
tinal or systemic inflammation, such as bacterial transloca-
tion and intestinal repair, and do not directly characterise 
functional deficits in the gut, such as deficits in macro-
nutrient or micronutrient absorption. The lactulose: 
mannitol ratio is regarded as indirect marker of dysfunc-
tion, but this is based on reported associations with the 
D- xylose test, a measure of carbohydrate absorption 
that is challenging to administer and has been reported 
only infrequently in the EE literature.29 30 Zinc metabo-
lism can be measured though carefully performed, dual 
stable isotope studies.19 Few other such tests are currently 
available.
Stable isotope- based tests have the potential to over-
come this limitation by assessing host function across 
multiple domains of EE. Labelled substrate tracers can be 
designed to target specific domains of intestinal epithelial 
activity.31 Substrate tracers labelled with 13C are particu-
larly promising for this purpose, as 13CO2 expired in the 
breath can be non- invasively sampled to obtain a quanti-
tative measure of substrate hydrolysis and absorption.
Intestinal sucrase- isomaltase (SI) activity has been iden-
tified as a potentially useful domain to target in a functional 
test of EE. SI is a small intestinal brush border enzyme 
that catalyses the hydrolysis of carbohydrates including 
starch, isomaltase and sucrose.32 It has a gradient expres-
sion along the small intestine, with highest expression in 
the duodenum and jejunum, and shows higher expres-
sion in the villi compared with the crypts. SI levels are 
reduced with mucosal injury but are relatively stable by 
race and age. Outside of a few higher- risk populations 
(eg, indigenous Greenlanders,33 inherited deficiencies 
are uncommon.34 35 SI activity is diminished in villus 
blunting,36 thus representing a possible surrogate marker 
of small intestinal function and integrity.37 Inflammatory 
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pathologies of the gut, namely autoimmune disorders, 
inflammatory bowel disease and intestinal inflammation 
caused by HIV and giardiasis, have also been shown to 
cause SI deficiency.38 A recent transcriptomic study also 
described SI activity as potentially altered by EE.39
Breath tests that characterise intestinal SI activity 
through the ingestion of 13C labelled sucrose have been 
employed in animal models and in childhood cancer 
chemotherapy as a biomarker of enteropathy.37 40 41 A 
13C- labelled sucrose breath test (13C- SBT) based on natu-
rally 13C enriched sucrose from maize, was also used 
by Ritchie et al to assess aboriginal Australian children 
from enteropathy settings.34 Threefold differences were 
observed between aboriginal and higher- socioeconomic 
status (SES) Australians children, and twofold differences 
among children with and without diarrhoea. However, 
this test was limited by the necessity for a large dose to 
produce an exhaled breath 13CO2 signal above basal 
13C 
abundance, making it unsuitable for routine use in very 
young children. Furthermore, between- population differ-
ences in the consumption of naturally 13C- enriched C4 
crops, such as maize and sugar cane, reduce the utility of 
this test as a diagnostic for EE or to compare the preva-
lence of EE between populations.
Inspired by this naturally enriched test, we recently 
developed a 13C- SBT based on highly enriched sucrose 
tracers. This test overcomes limitations of the previous 
test by dramatically reducing the quantity of substrate 
required, as well elevating exhaled 13CO2 substantially 
above the baseline value that might be expected due to 
diet, thereby improving the signal to noise ratio. To assess 
whether enriched 13C- SBT performance is altered among 
individuals with EE, we will conduct six integrated, 
complementary studies in two phases.
METHODS AND ANALYSIS
Our coordinated study design is summarised in table 1.
Phase 1
In the first phase of the study, our overall objective is to 
optimise and validate a protocol for a non- invasive stable 
isotope test based on an enriched sucrose substrate (13C- 
SBT), among adults and children. To accomplish this, 
we will complete five coordinated studies. We will first 
optimise the 13C- SBT protocol and second, validate the 
13C- SBT in successive adult and paediatric populations. 
We will then establish analytical validity (technical test 
performance), clinical validity (the test’s ability to accu-
rately and reliably identify a disorder of interest) and 
field usability (assessment of the test in the actual context 
where it would be used).42 43
The objective of the first study is to establish that the 
highly enriched sucrose tracers for an 13C- SBT report 
similar information in comparison to the original natu-
rally enriched 13C- SBT. We will conduct a cross- over study 
Table 1 Features of the coordinated research projects that make up the study protocol




  Study 1 Optimisation Cross- over n/a Healthy adults (N=20) Glasgow, UK




  Study 3 Validation Case–control Coeliac disease Children with coeliac (N=20)
Children with non- coeliac GI 
disorders (N=20)
Healthy child controls (N=20)
Adelaide, Australia
  Study 4 Validation Case–control Villous atrophy
Intestinal sucrase 
activity
Adults from an EE setting 
(N=20)
Healthy adult controls (n=20)
Lusaka, Zambia








  Study 6 Field utility and 
validation
Cross- sectional Urinary lactulose: 
rhamnose ratio
Length- for- age Z- score
Infants from EE settings 
(N=540)








EE, environmental enteropathy; n/a, not available; SES, socioeconomic status.
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of 20 adults using three commercially available sucrose 
tracers (13C6 fructose; 
13C6 glucose and 
13C12 sucrose). We 
will also determine whether the addition of unlabelled 
carrier sucrose is necessary to replicate the original 
‘flooding dose’ approach reported by Ritchie et al.34 To 
assess gut permeability, participants will also receive coad-
ministration of 5 g lactulose, 1 g rhamnose, 0.5 g xylose, 
0.2 g 3- O- methyl- D- glucose and 5 g sucralose dissolved in 
water.
The objective of the second study is to characterise 
the dose response of the 13C- SBT in response to three 
different doses of the intestinal sucrase inhibitor acar-
bose. A randomised cross- over trial of 20 adults will be 
conducted. Breath 13CO2 will be collected serially for 
4–6 hours and 13CO2 recovery compared across treat-
ments. Both studies 1 and 2 will be conducted in Glasgow, 
UK (University of Glasgow).
While the ideal ‘gold standard’ would be to breath 
test and biopsy children who are identified as having EE, 
from a logistical perspective, this study design is infeasible 
in the resource constrained environments where EE is 
prevalent. Therefore, the objective of the third study is to 
examine whether the 13C- SBT, optimised according to the 
protocol established in study 1, varies between children 
with clinically diagnosed coeliac disease presenting with 
gastrointestinal symptoms to outpatient clinics (n=20) 
versus healthy coeliac controls (n=20) and healthy non- 
coeliac controls (n=20) (Adelaide, Australia, Flinders 
University). In this study, active disease is defined as 
positive serology for specific IgA antibodies in patients 
on a gluten- containing diet, or in patients undertaking 
a gluten challenge, followed by endoscopic evaluation 
and histological examination of duodenal biopsy for 
characteristic features of coeliac disease (villus atrophy, 
crypt hyperplasia and mucosal inflammation), with a 
Marsh III classification considered coeliac positive. The 
degree of villous atrophy will be correlated to the patients 
13C- SBT result. Additionally, tissue biopsies, collected 
from inflamed and normal sections of small bowel, will 
be assayed ex vivo for SI activity and correlated with the 
13C- SBT. The non- coeliac control group includes chil-
dren presenting for endoscopy for non- coeliac disease, 
including abdominal pain and reflux disease, and do not 
present with any small intestinal pathology.
The objective of the fourth study is to validate the 13C- 
SBT against intestinal sucrase activity and villus atrophy 
among adults with and without EE. Both villus atrophy 
and intestinal sucrase activity are measured using biopsy. 
A case–control study design (n=20 cases from a high- 
risk enteropathy setting and n=20 controls) will be used. 
(Lusaka, Zambia, University of Zambia)
The objective of the fifth study is to correlate the 13C- 
SBT with an established, non- invasive biomarkers of EE 
(urinary LR ratio) and one secondary biomarker of EE 
(plasma kyurenine:tryptophan ratio) among children 
under 2 years of age from a high- risk enteropathy setting 
(n=30). (Iquitos, Peru, Asociación Benefica Proyectos 
de Informática, Salud, Medicina, y Agricultura (A.B. 
PRISMA) and the University of Virginia). A substudy 
will remeasure the 13C- SBT at 7 days to document test 
reproducibility.
Phase 2
In the second phase, we will conduct a multisite study 
in six resource- limited countries to determine the field 
usability of the optimised and validated 13C- SBT in diag-
nosing EE in children aged 12–15 months. The specific 
primary objectives are to assess the relationship between 
the 13C- SBT and the LR ratio among children 12–15 
months of age, and to assess the relationship between 
the 13C- SBT and child stunting. Our secondary objectives 
are to assess the relationship between the 13C- SBT and 
secondary biomarkers of EE. We will also conduct explor-
atory analyses to characterise the relationship between 
the 13C- SBT and child sex, SES, dietary diversity and 
household food security.
Study sites
This six study sites are: Dhaka, Bangladesh (the Interna-
tional Centre for Diarrhoeal Disease Research); Banga-
lore, India (St. John’s Research Institute, St. John’s 
National Academy of Health Sciences); Kingston, Jamaica 
(The Tropical Metabolism Research Unit of the Carib-
bean Institute for Health Research, University of West 
Indies); Kakamega, Kenya (Masinde Muliro University 
of Science and Technology); Iquitos, Peru44 (Asocia-
ción Benefica PRISMA and the University of Virginia) 
and Ndola, Zambia (Tropical Disease Research Centre). 
These sites represent a range of epidemiological contexts 
which enhances the cross- context applicability of study 
results.
Coordinated study design
Each site will enrol 100 infants between 12 and 15 months 
of age. This range was selected because it is within the 
window of infant growth faltering that implies clinical or 
public health relevance but is also old enough to reduce 
the influence of breastfeeding on LR performance and 
to permit a several hour fast during initial assessment 
of the test.45 46 At each site, 90 children will be recruited 
from areas deemed high risks for EE, due to a lack of 
improved water and sanitation infrastructure or because 
the known prevalence of stunting is relatively elevated. 
Ten relatively high SES infants from a nearby community 
will also be enrolled. All children will be recruited and 
enrolled through convenience sampling, either at the 
community level (if the study site has previously censused 
the community) or through child clinic visits. Exclusion 
criteria include the presence of Severe Acute Malnutri-
tion (weight for height z- score ≤−3 SD), HIV positive 
status, any chronic illness medical or surgical contrib-
uting to growth retardation, or weight- for- height z- score 
more than +2 SD.
Study procedures for each participating child are 
outlined in figure 1 and described in detail in online 
supplemental appendix 1. In brief, the 13C- SBT will be 
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assessed in each child at one time point, as well as a 
2- hour urinary LR test, an assessment of weight, length 
and body composition using the deuterium dilution 
technique (either saliva or urine), and a fasting plasma 
sample for the assessment of additional EE biomarkers. 
After 3 months, the height and weight measurement will 
be repeated. Each site will use the same harmonised study 
protocols for all data collection. Information about house-
hold SES, household food security (using the household 
food insecurity access scale), and child dietary diversity 
will also be asked of each caretaker using standardised 
instruments designed and validated for use across low- 
income and- middle income countries.47–49 Information 
about child morbidity and the consumption of C4 foods 
will also be collected using standardised questions. In 
certain sites with high rates of cell phone coverage, ancil-
lary morbidity data will also be collected by phone every 
2 weeks, although this will not be used in the primary 
or secondary analysis. Key study data are summarised in 
online supplemental appendix 2, and study forms are 
provided in online supplemental appendix 3.
All data will be digitised by site via double- data entry 
and will be managed in accordance with institutional 
norms and local ethical committee approvals. Each site 
will confidentially maintain personal information about 
enrolled participants as necessary for study administra-
tion. Deidentified data will be shared with the University 
of Michigan where centralised data consistency checks 
will be performed, and inconsistencies will be communi-
cated back to each site for resolution. After this process is 
complete, pooled analyses will be performed.
Outcomes and case definitions
13C breath tests can be summarised in several ways.50 
Based on expert opinion, cumulative per cent of dose 
recovered at 90 min post administration (cPDR90), and 
time to 50% recovery (T50), will be taken as our primary 
measures of the 13C- SBT. Other metrics for summarising 
the 13C- SBT test, at both specific time points and overall, 
will also be considered.
LR ratio: To assess the relationship between the 13C- SBT 
and EE, our case definition for EE, and primary outcome 
measure, will be based on the LR ratio, which is the most 
widely accepted, non- invasive test of EE. Because LR 
ratios vary by analytical platform26 and may also be influ-
enced by test administration procedures, cut- offs for ‘EE’ 
will be defined based on the empirical distribution of the 
data. To establish cut- offs for LR, the distribution of this 
variable among high- SES children (pooled across sites) 
will be examined (eg, LR ratios above the 90th percentile 
for upper SES children will be regarded as ‘elevated’). If 
insufficient numbers of higher- SES children are recruited, 
or if a subset of higher- SES children cannot be recruited 
across all sites, cut- off values for LR will be determined 
based on internal study percentiles (eg, below vs above 
the median) or on cut- offs from the literature.51 If the 
outcomes of the phase 1 studies support evidence for a 
LR cut- off based on the extent of villous atrophy, this will 
also be considered.
Anthropometry: We will use WHO growth standards 
to define length for age Z- score (LAZ), weight for age 
Z- score (WAZ) and weight for length Z- score. Stunting, 
Figure 1 Flow diagram for phase 2 coordinated study protocol shown here is the timeline of participant activities. Darker grey 
boxes represent core study activities, while light grey boxes indicate activities that some, but not all, study sites will undertake. 
Primary and secondary study aims are based on core activities.
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underweight and wasting will be defined based on WHO 
growth standards (≤ −2 Z- scores length for age, weight for 
age and weight for length).52
Our primary outcome measures are
1. Comparison of the13C- SBT to the LR ratio, to the per 
cent lactulose recovery, and to the percent rhamnose 
recovery.
2. Characterise the relationship between the 13C- SBT and 
child anthropometry (LAZ and WAZ).
3. Characterise the relationship between 13C- SBT and 
childhood linear growth (change in LAZ) over 3 
months and over 6 months.
Secondary outcome measures
1. Assess the relationship between the13C- SBT and faecal 
myeloperoxidase concentration.
2. Assess the relationship between the 13C- SBT and serum 
fatty acid binding protein concentration.
3. Assess the relationship between the 13C- SBT and the 
kynurenine tryptophan ratio.
4. Assess the relationship between the 13C- SBT and faecal 
alpha- antitrypsin concentration.
Other prespecified outcome measures are
1. Reproducibility of the 13C- SBT.
We will assess the coefficient of variation and correla-
tion coefficient between repeated cumulative percent 
of dose recovered at 90 min postadministration on sep-
arate SBT tests administered 1 week apart done on the 
same child (Peru site only).
2. Assess the relationship between epidemiological fac-
tors and the 13C- SBT.
We will determine if significant associations exist be-
tween 13C- SBT measured as cPDR90/T50 and the 
Water Assets Maternal Education and Income (WAMI 
index). The WAMI index is a previously validated com-
posite index of environmental variables to create an 
index that expresses the socioeconomic and physical 
environment in diverse geographical contexts.47
Sample size
The sample size for the phase 2 study was predetermined 
(N=10 upper SES and 90 lower SES children per site), 
power calculations were conducted. Calculations were 
based on previously reported Pearson’s correlations of 
0.67 (95% CI 0.42 to 0.82) between the naturally enriched 
13C- SBT and LR.34 The current test, using highly enriched 
sucrose, is expected to be more sensitive than the original 
test, so sample size estimates are regarded as conservative. 
Assuming the Pearson’s correlation between the enriched 
13C- SBT and LR is similar, 90 children per site is suffi-
cient to estimate the correlation between the two tests 
with an SD of 0.58 (95% CI 0.55 to 0.79).53 The minimal 
detectable correlation within each site, would be 0.31.54
Between sites, we estimate statistical power to detect 
meaningful differences between children with and 
without EE, based on a cut- off of the LR ratio. The 
proportion of children who will be classified as having 
EE relative to this these cut- offs is unknown, so the esti-
mated detectable difference was calculated across a range 
of values (10%–50%). We estimate that differences in 
the 13C- SBT on the order of 0.60 standard deviations 
(50% prevalence of EE) to 0.99 SD (10% prevalence of 
EE) will be detectable with 80% power. For comparison, 
Ritchie observed differences in the 13C- SBT cumulative 
percentage of dose recovered at 90 min between healthy 
Aboriginal and non- Aboriginal children on the order of 
~0.84 SD, and differences between Aboriginal children 
with and without acute diarrhoea on the order of ~0.92 
SD.
Power calculations were also performed to assess the 
relationship between the 13C- SBT and child stunting 
based on the known prevalence of stunting in each site 
(table 2).
Data analysis plan
All analyses will be stratified by site and then pooled. 
Analysis stratified by site will be limited to bivariable 
comparisons, and pooled data will be used to construct 
multivariable models, using either fixed or random 
effects to account for site.
We will examine the relationship between the 13C- SBT 
and LR both continuously, and as dichotomous variables. 
Continuous analyses will include calculation of both site- 
specific and pooled correlation coefficients (to provide 
direct comparison to Ritchie34 and regression models 
will be developed where the dependent variables will be 
log- transformed LR, and the independent variable will 
be cPDR90 and T50. For dichotomous analyses, Receiver 
Operating Characteristic (ROC) curves will be used to 
calculate the sensitivity and specificity of be cPDR90 and 
T50 cut- offs to predict relatively elevated LR test results. 
We will also examine the association between the 13C- SBT 
and lactulose and rhamnose excretion individually.
To characterise the relationship between the 13C- 
SBT test and child anthropometry, we will compare be 
cPDR90 and T50 values for the 13C- SBT and concurrently 
measured LAZ and WAZ. We will also consider fat mass 
and fat- free mass. Nutritional status will be analysed both 
continuously and will dichotomised (ie, into stunted 
and non- stunted). T- tests will be used to compare be 
cPDR90 and T50 between the stunted and non- stunted 
groups within sites, and simple and multivariable linear 
regression models including random effects for country 
membership, where the dependent variables will be LAZ, 
WAZ and the independent variable will be 13C- SBT. In 
addition, we will consider adjustment for factors such 
as the age, sex, breastfeeding status and recent illness 
history of the child.
Our first secondary objective is to assess the relationship 
between the 13C- SBT and secondary biomarkers of EE. 
This activity will be contingent on the availability of these 
biomarker results from a sufficient number of infants 
across the study sites. Following the prior approachs,27 55 
the relationship between EE biomarkers will be explored 
and EE scores will be generated via principal compo-
nents analysis, partial least squares regression, or other 
variable reduction techniques, and comparisons between 
 on D
ecem









pen: first published as 10.1136/bm






7Lee GO, et al. BMJ Open 2020;10:e035841. doi:10.1136/bmjopen-2019-035841
Open access
be cPDR90 and T50 and these scores will be examined 
similarly to LR.
Following previous approaches, we will examine the 
association between the 13C- SBT and subsequent change 
in WAZ, and LAZ,25 56 57 which enhances the comparably 
of our results to those of other studies. We will again 
consider adjustment for factors that may influence child 
growth trajectory such as the age, gender, breastfeeding 
status, and recent illness history of the children in pooled 
models only.
Finally, we will conduct exploratory analyses. To assess 
the reproducibility of the 13C- SBT we will examine 
the coefficient of variation and correlation coefficient 
between repeated tests from the same child (Peru site 
only). We will also examine the relationship between the 
13C- SBT and child sex, SES, dietary diversity and house-
hold food security. Regression models will be developed 
where the dependent variable will be the result of the 13C- 
SBT test (transformed if necessary) and the independent 
variables will include factors that may be associated with 
the infant gut function, including breastfeeding, dietary 
diversity, age, sex, food security, history of recent illness 
and SES scores.47 If between- site differences in 13C- SBT 
are observed, the models will include site- level random 
intercepts.
Patient and public involvement
No patient involvement.
Ethics and dissemination
Each study protocol has been approved (Zambia, 
Australia, Peru, Bangladesh, India, UK, Zambia, Kenya) 
or is pending approval (Jamaica) by the institutional 
review board or boards relevant to that study site. Written 
informed consent will be obtained from the participant 
themselves, and/or the legal guardian of each partici-
pant, by members of each local study team. In both the 
phase 1 and the coordinated phase 2 studies, each study 
site will use a unique consent form, reflective of both of 
core study activities and any site- specific activities also 
being performed.
We will publish and disseminate our results once the 
project is complete. By conducting the field usability 
phase of our study across six countries, our test, if shown 
to be informative of EE, will demonstrate strong evidence 
for utility across diverse, low- income and middle- income 
country paediatric populations.
DISCUSSION
We propose to optimise, validate and assess the field 
usability of a 13C- SBT to evaluate EE. The research team 
brings together experts in stable isotopes, biochemistry, 
gastroenterology, human nutrition and epidemiology, as 
well as field teams with extensive expertise conducting 
human research in resource- limited settings. This breadth 
of expertise is necessary to overcome previous limitations 
of EE research. Proposed EE biomarkers have often been 
carried over from studies of severe gastrointestinal disor-
ders, such as coeliac disease, into enteropathy settings, 
with unclear biological interpretation and without vali-
dation against the ‘gold- standard’ definition of EE. In 
other instances, analytical variability has hindered cross- 
study or cross- context comparisons of test performance.26 
Our staged validation approach and multisite design are 
intended to overcome these limitations and may serve as 
a template for future EE biomarker studies.
Table 2 Power calculations are based on the primary comparison of stunted to non- stunted children
Country
Estimated prevalence
of stunting, % Sample size
Detectable difference in
13C- SBT between stunted and
non- stunted (per SD)
Bangladesh 36 90 0.62 SDs
India 27 90 0.67 SDs
Jamaica 20 90 0.74 SDs
Kenya 26 90 0.67 SDs
Peru 38 30 0.61 SDs
Zambia 40 90 0.61 SDs
Pooled- no design effect 30.4 480 0.28 SDs
Pooled – design effect=0.9 30.4 432* 0.30 SDs
Pooled- design effect=0.7 30.4 336* 0.34 SDs
Pooled- design effect=0.5 30.4 240* 0.40 SDs
Table 2 shown here are estimated detectable differences in the 13C- SBT between stunted and non- stunted children, based on 
the estimated prevalence of stunting in specifically proposed study communities (estimates of stunting prevalence provided 
by study community). The percentage of variability in the 13C- SBT based on site is unknown, so a range of design effects 
(1.0–0.5) are provided.
*Asterisks refer to the overall sample size adjusted for the design effect.
13C- SBT, 13C- sucrose breath test .
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The protocol is relatively intensive, with the phase 2 
study requiring 4- hour breath collections and 2- hour urine 
collections from 600 infants. This decision to emphasise 
the comprehensive testing of a relatively smaller number 
of children was deliberate. If the study results support the 
utility of the 13C- SBT, future work would aim to shorten 
and streamline our protocol for future clinical and epide-
miological research.
At present, there is a true deficiency in the number of 
non- invasive tests to measure intestinal function. The crit-
ical evaluation of this test will add to collective knowledge 
if findings affirm, refute or partially affirm the utility of 
the test. This study will ascertain whether a stable isotope 
breath test can report information on the functional 
activity of an important small intestinal enzyme, or not. 
This will serve as an important paradigm on the poten-
tial utility of other functional breath tests which could be 
used to characterise EE. Looking ahead, 13C breath tests 
have potential utility for better understanding multiple 
other enzymes and factors of nutrient uptake in addition 
to SI activity. The digestion of proteins and uptake of 
one or more amino acids and/or peptides through the 
development of probes for peptidases would be a logical 
next step, as would the integration of zinc assays to probe 
multiple nutrient uptake capacities concurrently. The 
overarching vision of the coordinated research project is 
the eventual development of a breath test that, like the 
urea breath test for Helicobacter pylori, can be deployed 
to rapidly identify children with potential EE. Although 
the 13C- SBT we describe here is non- invasive and feasible 
in low- resource settings, the analysis of these samples 
currently cannot be performed at the point of care. 
However, with advancing breath analysis technology, 
these tests are becoming less expensive and more field- 
deployable, opening these approaches to a wider user 
base and especially to researchers and clinicians in low- 
income and middle- income countries.
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Appendix 1: Unified Phase 2 Study Protocol 
Phase 2 study protocol: The 13C-SBT, LR test, and D2O dilution to assess body composition will 
be completed during a single visit with each participant. The study team will screen for recent 
diarrhea, antibiotic usage, and anti-inflammatory usage in the past month (anti-inflammatories are 
known to induce transient intestinal permeability1 as well as enterocyte injury). If any of these are 
reported by the parents, the appointment will be schedule one month from the date of the diarrheal 
episode or antibiotic/anti-inflammatory use.  
Guardians will be asked to fast their child for one hour prior to the appointment. Time will be given 
for the child to settle and adjust to their surroundings, including time for the child to play with, and 
become familiar with, the breath sampling equipment. Two baseline breath collection 
measurements will be completed, using a cannula apparatus for breath collection, consisting of a 
piece of PVC tubing taped just underneath the child’s nostril and controlled with a 3-way tap, or, 
if the field team prefers it, a face mask and breath collection bag. Exhaled breath will then be 
transferred to Labco Exetainers (evacuated tubes Labco Order No 428W or 439W, Burlington, 
North Carolina, USA) either by positive displacement (syringe) or using evacuated exetainer 
(bag). A baseline urine sample will be collected, and, for sites using deuterium dilution technique 
with analysis of saliva samples to assess body composition2 (Bangladesh, India, Kenya, and 
Zambia), a baseline saliva sample will be collected. 
To avoid 13C12-sucrose loss, the 13C12-sucrose solution and the LR solution will be administered 
separately. First, the 40 mg/mL 13C12-sucrose solution will be administered at a dosage of 10µL 
per kg body weight (spiked in 1mL of drinking water). For example, for a child weighing 10kg, the 
dosage will be 100µL spiked in 1mL of drinking water. This will be followed a 2mL chaser of 
drinking water to rinse the vial.  
Secondly, a 9mL of drinking water spiked with 1g lactulose and 0.2g rhamnose will be 
administered, and again a 2 mL chaser of drinking water will be used to rinse the vial. The total 
volume (1mL sucrose solution + 2mL chaser + 9mL LR solution + 2mL chaser) is 14 mL. 
If the child spits out, vomits, or fails to swallow all the sugar solution, the test will be canceled and 
re-scheduled. After the child has consumed the sugars, a standard dose of deuterium oxide (D2O) 
based on IAEA protocols will also be administered to the child. As soon as both the sugar solutions 
and the D2O have been administered the child will be encouraged to drink water. After 90 minutes, 
the child will be given a standardized meal. The choice of standardized meal will be site-specific 
but may include egg, legumes, or rice and will not include any sugary foods or dairy products.  
Breath sample collection: Using a stopwatch, breath samples will be collected every 15 minutes 
for the first 90 minutes following the administration of the sugar solution, and then every 30 
minutes until 240 minutes (4 hours) have passed. 
Urine sample collection: All urine passed in the 30-120 minutes of the test will be collected and 
combined for analysis, and any urine passed in the 120-300 minutes of the test will be collected 
and combined separately. The volume of all voids will be recorded. Both 2- and 5-hour LR tests 
are common in the literature3–5, with some evidence that 2-hour urine collections better capture 
small intestinal, rather than colonic, absorption5. Here, both measures will be collected to enhance 
comparability with prior reports. 5-hour recoveries of lactulose and rhamnose will be calculated 
as the weighted average of the 30-120 and 120-300-minute samples. Samples will either be 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
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 doi: 10.1136/bmjopen-2019-035841:e035841. 10 2020;BMJ Open, et al. Lee GO
stored with chlorhexidine or will be collected without preservative and stored immediately at -80. 
We will examine whether chlorhexidine results in interference during LC-MS/MS analysis. 
Saliva sample collection: For sites measuring D2O via saliva, the sample will be collected between 
180 and 210 minutes of the test. 
Plasma sample collection: After the breath/urine collection is complete, a second visit will be 
scheduled with study families to collect a plasma sample. Families will be asked to fast the child 
for 6 hours prior to the blood draw, and 2mL of blood will be collected in K2 EDTA. Following 
collection, the sample will be centrifuged and stored at -80C pending analysis. 
Anthropometry and questionnaire data: The length, weight, and head circumference of each child 
will be measured, as will the height and weight of their mothers. Standard questionnaires to 
capture key socio-economic6 and demographic information, child dietary diversity (including 
recent consumption of C4 foods (e.g. maize, sugar cane, and sorghum or millet), and household 
food insecurity7, will be administered. Three months following the initial test, a third appointment 
will be made with the family to re-measure anthropometry, and to administer a questionnaire 
asking about morbidity over the past three months. Key data are summarized in Appendix 2.   
Additional site activities: In addition to coordinated study activities, some activities will only be 
undertaken by one, or a sub-group, of study sites. In one site (Peru), the 13C-SBT test will be 
repeated after 2 days on 40 children, to assess test reproducibility. Several secondary EE 
biomarker assays of interest were also identified, to be assayed by sites resource permitting. 
These include, in order of priority, plasma fatty acid binding protein (FABP); plasma LPS binding 
protein (LPS-BP); and stool alpha-1-antitypsin (AAT) and stool myeloperoxidase (MPO).  
Laboratory analyses: Breath samples from four sites (Peru, Jamaica, Kenya, and Zambia) will be 
sent to Dr. Roger Yazbek at the South Australian Breath Analysis Research Laboratories (SABAR 
Lab) where they will be analyzed via ABCA Isotope Ratio Mass Spectrometry. To minimize of 
inter-platform variability in dual-sugar testing8, urine samples for lactulose and rhamnose will be 
performed either on a single platform, on two or more standardized platforms (to be determined). 
Breath sample analysis for Bangladesh and India will be analyzed at Saint John’s Research 
Institute, Bangalore. 
Deuterium dilution testing: Based on available instrumentation, one site (India) will assess body 
composition analysis through D2O analysis of urine, and four sites (Peru, Jamaica, Bangladesh, 
Kenya, and Zambia) will use saliva. Deuterium equilibrates faster in saliva compared to urine9 and 
deuterium dilution analysis in saliva requires a higher dose and different instrumentation (Fourier 
Infrared Spectroscopy versus Isotope Ratio Mass Spectrometer) compared to urine sampling.  
However, the collection of urine or saliva for total body water analysis has been standardized and 
validated, with comparable performance demonstrated in infants younger than those we propose 
to measure in this study10. Deuterium enrichment of urine will be assessed using a Delta V 
advantage Isotope Ratio Mass Spectrometer (Thermo Fisher scientific Inc)11.  Saliva samples will 
be measured for their deuterium enrichment in duplicate by Fourier Transformed Infrared 
Spectrophotometry (4500t FTIR, Agilent Technologies, CA, USA).  
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Appendix 2: Key Study Data 
Key variable Detail 
Child age Months 
Child sex Male; female 
  
Anthropometry: 
Birthweight  kg 
Baseline weight kg 
Baseline length cm 
FM Fat mass, measured by deuterium dilution  
FFM Fat free mass, measured by deuterium dilution 
Weight at 3-month follow-up kg 
Length at 3-month follow up cm 
Maternal weight kg 
Maternal height cm 
  
Questionnaire data: 




Using the water and sanitation, eight selected assets, 
maternal education, and household income (WAMI) 
score47 
Child dietary diversity score Adapted to capture consumption of C4 foods 
Recent child morbidity Diarrhea in past month 
  
EE Biomarkers: 
LR Urinary lactulose: rhamnose ratio 
FABP Plasma fatty-acid binding protein 
KT Plasma kynurenine: tryptophan ratio 
MPO Fecal myeloperoxidase 
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Child ID Code:  S B  T -          
  
 
Urine and Breath Collection Form Version 1.3 
 Question Code Response 




02 Today’s date (DD/MMM/YY) 
   /   /   
 
03 Time of arrival to Study Clinic Time (24 h Scale; HH:MM) 
  :   
 
Screening questions 
04 Diarrhea in past month Yes = 01  No = 00   
 
05 Antibiotics in past month Yes = 01  No = 00   
 
06 
Anti-inflammatories in past month  
(ibuprofen, naproxen, aspirin, methenozol) 
(paracetamol is OK) 
Yes = 01  
No = 00   
 
If any of these questions (03, 04, 05) was yes, please re-schedule the test one month from the date of the diarrhea or 
antibiotic/NSAID use 
07 Standard meal given (rice: legume mix, egg) or breastmilk  Tick Idly /Kichadi/ Hard-boiled egg 





















Time of Collection Comments 
(please note 
any spillage) 




Baseline    :   
 
 
  *Use baseline urine for LR and Body composition (D2O) 
 
DO NOT ADMINISTER SUGAR SOLUTION UNTIL THE CHILD HAS FULLY VOIDED THEIR BLADDER AND THE 
TIME IS 1 HOUR FROM THE LAST MEAL  
Vial label of 13C12-sucrose solution   
Time the 13C12-sucrose was first consumed:    :   
 








Time the LR solution was consumed:  Start time: _ _ : _ _           End time: _ _ : _ _     
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Child ID Code:  S B  T -          
  
 
How many minutes did it take the child to 
consume the LR solution in full? 01-20 minutes   
 
Was the LR solution consumed in full? 
Weight of pre-weighed tissue =  
Weight of soaked tissue =  
Yes = 01  
No = 00   
 
If the child spits out, vomits, or fails to swallow all the sugar solution, the test cannot be completed. Please stop and re-
schedule the test for another day. 
Total volume (mL) of deuterium water consumed      
 
Total volume (mL) of chaser consumed 
 
    
 
Was the deuterium dose consumed in full? 
Weight of pre-weighed tissue =  
Weight of soaked tissue = 
Yes = 01  
No = 00     
 
A pre-weighed napkin should be placed under the neck to collect any spill from the dose. This should be weighed 
immediately after or placed in a small airtight container to avoid evaporation if immediate weighing is not possible. 
Start collection: Encourage the child to drink water throughout the test. 
Breath 
sample 
tube time  
Exact collection 
time 


















15 minutes    Do not collect urine for the first 30 minutes after the child 
consumes the sugar solution 
30 minutes    
45 minutes    
30 to 90 
minutes 
   
60 minutes       
75 minutes       
90 minutes       
At this time, please give the child the standardized meal 
Standard meal given (rice: legume mix, egg) or breastmilk Tick Idly /Kichadi/ Hard-boiled egg/ milk without sugar/ milk + beet sugar 
Time of consumption of standard meal  
Time (24 h 
Scale; 
HH:MM) 
  :   
 
120 minutes   
 
90 to 120 
minutes 
   
   
   




   
180 minutes       
Urine        
210 minutes       
240 minutes       
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10 Did any breastfeeding occur in the first 90 minutes of the test? (if the mother needed to comfort the child) 
Yes = 01  
No = 00   
 
11 
Did the child consume any non-breastmilk liquids or foods during the first 90 
minutes of the test?  
(excluding water, which should be encouraged throughout the test) 
Yes = 01  
No = 00   
 
12 Weight of sipper with water at start of experiment (g)     
 
13 Weight of sipper with water at end of experiment (g)     
 
Anthropometry (take measurement in triplicates) 
1 Height (cm)   .  
 
  .  
 
  .  
 
2 Weight (kg)   .   
 
  .   
 
  .   
 
3 Head circumference (cm)   .  
 
  .  
 
  .  
 
4 MUAC (cm)   .  
 
  .  
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Child ID Code:                
  
Breath Sample Reception in Laboratory Version 1.0 
 Question Code Response 
01 Study researcher/ Nurse/ 
Fieldworker ID 
 
      
 
02 Todayʼs date (DD/MMM/YY)    /   /   
 
03 Sample ID:  
04 Time of arrival of sample at 
laboratory 
Time (24 Hr Scale; 
HH:MM)   :   
 
05  






 15-minute sample A  15-minute sample B 
 30-minute sample A  30-minute sample B 
 45-minute sample A  45-minute sample B 
 60-minute sample A  60-minute sample B 
 75-minute sample A  75-minute sample B 
 90- minute sample A  90-minute sample B 
 120-minute sample A  120-minute sample B 
 150-minute sample A  150-minute sample B 
 180-minute sample A  180-minute sample B 
 210-minute sample A  210-minute sample B 





Breath samples should be labeled as follows: Study code + site code + participant code + timepoint + replicate 
identifier (A or B) e.g. SBT-ZAM1-P1-T60-A 
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Child ID Code:                
  
Urine Reception in Laboratory Version 1.0 
 Question Code Response 
01 Study researcher/ Nurse/ 
Fieldworker ID 
 
      
 
02 Todayʼs date (DD/MMM/YY)    /   /   
 
03 Sample ID:  
04 Time of arrival of sample at 
laboratory 
Time (24 Hr Scale; 
HH:MM)   :   
 
05 Number of aliquots of urine 
collected from 30 - 90 minutes 
(should be 4 aliquots of 250 µL) 
01-04     
 
06 Number of aliquots of urine 
collected from 90 minutes to 120 
minutes 
 
(should be 2 aliquots of 250 µL) 
01-02     
 
07 Number of aliquots of urine 
collected from 120 minutes to 300 
minutes  
(should be 2 aliquots of 250 µL) 
If applicable 




Urine samples should be labeled as follows: Study code + site code + participant code + timepoint (in minutes, 
from start time) + replicate identifier (A, B, C, D) 
 e.g.  30-90-minute urine:  SBT-ZAM1-P001-T30-A 
 90-120-minute urine:  SBT-ZAM1-P001-T90-A 
120-300-minute urine:  SBT-ZAM1-P001-T120-A 
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Child ID Code:                
  
Blood Sample Collection Version 1.0 
(6 hours postprandial) 
 Question Code Response 
01 Study researcher/ Nurse/ 
Fieldworker ID 
 
      
 
02 Todayʼs date (DD/MMM/YY)    /   /   
 
03 Before starting the test, when was 
the last time the child ate (either 
breastmilk or solid foods) 
(post prandial for how many 
hours) 
Time (24 Hr Scale; HH:MM)     :     
 
If the child has not fasted overnight, please reschedule the blood draw: 
04 Time of blood collection: 
Time (24 Hr Scale; HH:MM)     :     
 
05 Tube with up to 2mL blood 
collected? 
Yes=01 




Blood samples should be labeled as follows: Study code + site code + participant code + timepoint + replicate 
identifier (A or B) e.g. SBT-ZAM1-P1-T60-A 
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Child ID Code:                
  
Blood Sample Reception Version 1.0 
 Question Code Response 
01 Study researcher/ Nurse/ 
Fieldworker ID 
 
      
 
02 Date of blood collection 
(DD/MMM/YY) 
   /   /   
 
03 Date of blood arrival in laboratory    /   /   
 
04 Time of arrival 
Time (24 Hr Scale; HH:MM)     :     
 
05 Tube 1 with up to 2mL blood 
received?  
Yes=01 
No=00     
 
06 Evidence of hemolysis? No=00 
Slight=01 
Severe=02      
07 Sample ID:  
  
08 Date of Centrifugation: 
   /   /   
 
09 Time of Centrifugation: Time 
(24 Hr Scale; HH:MM)     :     
 
10 Number of 500µL Plasma 




Blood samples should be labeled as follows: Study code + site code + participant code + timepoint + replicate 
identifier (A or B) e.g. SBT-ZAM1-P1-T60-A 
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Child ID Code:                
  
Enrollment Form Version 1.1 




      
 
02 Todayʼs date (DD/MMM/YY)  
    /     /     
 
A. Child information and anthropometry 
01 Date of birth (DD/MMM/YY)      /     /     
 
02 Sex of child Male=01 
Female=02     
 
03 Birthweight (kg) * 
(from birth record, if available)      .     
 
04 Current weight (kg) *      .     
 
05 Current length (cm)      .   
 
06 Current head circumference (cm)      .   
 
B. Maternal anthropometry 
01 Mother’s date of birth 
     /     /     
 
02 Is the mother currently pregnant? 
 
Yes = 01  
No = 00     
 
03 Mother’s Weight (kg)  
      .     
 
04 Mother’s Height (cm)        .   
 
C. Socio-economic Information (WAMI) 
 
Please explain to the mother that these questions are standardized questions used around the world, so 
some questions may be more applicable to them than others. 
 
01 Was this child chosen for 
participation in the study because 
they come from a low-SES 
community, or a high SES 
community? 
Low SES= 01  
High SES = 02     
 
02 What is the main source of 




Piped into dwelling = 01 
Piped to yard/plot = 02 
Public tap/stand pipe= 03 
Tube well or borehole = 04 
Protected well = 05 
Unprotected well = 06 
Surface water (river/ dam/ lake/pond/ 
stream/canal/irrigation canal) = 07 
Other = 08 
    
 
02a If other, describe: 
  
03 What is the main source of water 
used by your household for other 
purposes such as cooking and 
hand-washing? 
Piped into dwelling = 01 
Piped to yard/plot = 02 
Public tap/stand pipe= 03 
Tube well or borehole = 04 
Protected well = 05 
Unprotected well = 06 
Surface water (river/ dam/ lake/pond/ 
stream/canal/irrigation canal) = 07 
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Child ID Code:                
  
Other = 08 
03a 
 
If other, describe: 
  
04 What kind of toilet facility do 
members of your household 
usually use? 
No facility/bush/field or bucket toilet = 01 
Pit latrine without flush = 02 
Flush to piped sewer system = 03 
Flush to septic tank = 04 
Flush to pit latrine = 05 
Flush to somewhere else = 06 
Other = 07 
    
 
04a If other, describe: 
  
05 Do you have a separate room 
which is used as a kitchen?  
Yes = 01 
No = 00     
 
06 Does any member of your 
household have a bank account? 
Yes = 01 
No = 00     
 
07 Does your household have a 
mattress? 
Yes = 01 
No = 00     
 
08 Does your household have a 
refrigerator? 
Yes = 01 
No = 00     
 
09 Does your household have a 
television? 
Yes = 01 
No = 00     
 
10 Does your household have a 
table? 
Yes = 01 
No = 00     
 
11 Does your household have a chair 
or bench? 
Yes = 01 
No = 00     
 
12 How many rooms are there in 
your house? 
Yes = 01 
No = 00     
 




    
 
14 Have you (the mother of the study 
child) ever attended school? 
If no, skip to question 18. 
Yes = 01 
No = 00     
 
15 How many years of schooling 
have you completed? 
00-20     
 
16 If younger than 25 years old: Are 
you 
currently attending school or 
college? 
Yes = 01; No = 00     
 
17 What is the average monthly 
income for the entire household? 
 
                
 
18 Currency  I = Indian rupees; J = Jamaica dollars; 
K=Zambian kwacha; P = Peruvian soles; 




D. Child’s dietary diversity 
01 
 
Are you breastfeeding <CHILD>? 
If NO, then skip to Q.6 
Yes = 01 




Last night, how many times did 
you breastfeed <CHILD> from 
sunset to sunrise? 
00-99     
 
01b Yesterday, during the day, how 
many times did you breastfeed 
<CHILD>? 
00-99     
 
02 Do you give <CHILD> infant 
formula? If NO, then skip to Q.9 
Yes = 01 
No = 00     
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Child ID Code:                
  
02a Last night, how many times did 
you feed <CHILD> formula from 
sunset to sunrise? 
00-99     
 
02b Yesterday, during the day, how 
many times did you feed 
<CHILD> formula? 
00-99     
 
03 Do you give <CHILD> other milks, 
such as tinned, powdered or fresh 
animal milk? If NO, then skip to 
Q.12 
Yes = 01  
No = 00     
 
03a Last night, how many times did 
you feed <CHILD> animal milks 
from sunset to sunrise? 
00-99     
 
03b Yesterday, during the day, how 
many times did you feed 
<CHILD> animal milk? 
00-99     
 
 
Yesterday, during the day or last night, did <CHILD> have: 
04 Plain water Yes = 01 
No = 00     
 
05 Tea, coffee <local examples>? Yes = 01 
No = 00     
 
06 Fruit or vegetable juices? Yes = 01 
No = 00     
 
07 Any other liquids, such as sugar 
water, thin soup or broth, 
carbonated drinks <local 
examples> 
Yes = 01 
No = 00     
 
08 Is <CHILD> eating any semi-solid, 
mashed or solid foods? If NO, go 
to Q24 
Yes = 01 
No = 00     
 
    
Thinking about yesterday, during the day and at night, did <CHILD> have any of these foods, even if they 
were in combination with other foods? 
 
09 Maize? Yes = 01 
No = 00     
 
10 Sorghum? Yes = 01 
No = 00     
 
11 Millet (any kind)? Yes = 01 
No = 00     
 
12 Sugar cane or cane-derived sugar Yes = 01 
No = 00     
 
13 Rice, porridge, bread, noodles or 
other foods made from grains? 
(do not include foods made from 
maize, sorghum, or millet) 
Mention <local examples> 
Yes = 01 
No = 00     
 
14 White potatoes, white yams, 
manioc, or other foods made from 
roots? Mention <local examples> 
Yes = 01 
No = 00     
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15 Carrots, squash, or sweet 
potatoes that are yellow or orange 
inside? Mention <local examples> 
Yes = 01 
No = 00     
 
16 Any dark green leafy vegetables 
such as spinach? Mention <local 
examples> 
Yes = 01 
No = 00     
 
17 Foods made with beans, lentils, 
peas, corn, ground nuts? Mention 
<local examples> 
Yes = 01 
No = 00     
 
18 Ripe mangoes, papayas, or other 
sweet yellow/orange or red fruit? 
Mention <local examples> 
Yes = 01 
No = 00     
 
19 Any other fruits or vegetables 
such as banana, apple, oranges, 
tomatoes, avocado? Mention 
<local examples> (not including 
sugar cane) 
Yes = 01 
No = 00     
 
20 Liver, kidney, heart or other organ 
meats? Mention <local examples> 
Yes = 01 
No = 00     
 
21 Any meat, such as chicken, beef, 
lamb, goat, duck (others)? 
Mention <local examples> 
Yes = 01 
No = 00     
 
22 Eggs? Mention <local examples> Yes = 01 
No = 00     
 
23 Fresh or dried fish or shellfish? 
Mention <local examples> 
Yes = 01 
No = 00     
 
24 Cheese, yogurt or other dairy 
products? Mention <local 
examples> 
Yes = 01 
No = 00     
 
25 Any sugary foods such as 
pastries, cakes or biscuits? 
Mention <local examples>  
Yes = 01 
No = 00     
 
26 Any commercially available foods 
for infants or young children? 
Mention <local examples> 
Yes = 01 
No = 00     
 
27 Yesterday, counting meals and 
snacks, how many times did you 
feed <CHILD>? 
00-99     
 
28 How would you describe your 







    
 
E. Food Security (HFIAS) 
01 In the past four weeks, did you 
worry that your household would 
not have enough food? 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03      
02 In the past four weeks, were you 
or any household member not 
able to eat the kinds of foods you 
preferred because of a lack of 
resources? 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03      
03 In the past four weeks, did you or 
any household member have to 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03 
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eat a limited variety of foods due 
to a lack of resources? 
04 In the past four weeks, did you or 
any household member have to 
eat some foods that you really did 
not want to eat because of a lack 
of resources to obtain other types 
of food? 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03 
    
 
05 In the past four weeks, did you or 
any household member have to 
eat a smaller meal than you felt 
you needed because there was 
not enough food? 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03 
    
 
06 In the past four weeks, did you or 
any other household member 
have to eat fewer meals in a day 
because there was not enough 
food? 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03 
    
 
07 In the past four weeks, was there 
ever no food to eat of any kind in 
your household because of lack of 
resources to get food? 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03 
    
 
08 In the past four weeks, did you or 
any household member go to 
sleep at night hungry because 
there was not enough food? 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03 
    
 
09 In the past four weeks, did you or 
any household member go a 
whole day and night without 
eating anything because there 
was not enough food? 
 
 
No = 00 
Rarely = 01 
Sometimes = 02 
Often = 03 
    
 
F. Child Morbidity 
01 Does the child have diarrhea today? Yes = 01  
No = 00 
Doesn’t know = 88     
 
02 Over the past 1 week (including 
today), has your child had diarrhea? 
Yes = 01  
No = 00 
Doesn’t know = 88     
 
03 If yes to 02, for how many days? 
01-07     
 
04 Over the past 4 weeks (including 
today), has your child had diarrhea? 
Yes = 01  
No = 00 
Doesn’t know = 88     
 
05 If yes to 04, how many separate 
episodes? 
01-20 
Doesn’t know = 88     
 
06 How many days per episode?  
 
 
Note: Episodes must be separated by 
at least 2 days without diarrhea                
01-20 
Doesn’t know = 88 
 
a. First episode     days 
    
b. Second episode     days 
    
c. Third episode     days 
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07 In how many episodes was 
blood/pus/mucus seen?      
 
(The total number of episodes    
01-20 
Doesn’t know = 88     
 
CHRONIC DIARRHEA (Change in consistency of stools with passing of loose or watery stools lasting for MORE THAN 14 
days) 
08 Over the past 4 weeks (including 
today), has your child had diarrhea 
for MORE THAN 14 days? 
Yes = 01  
No = 00 
Doesn’t know = 88     
 
09 Were there any hospitalizations in 
the last 4 weeks? 
 
If no, skip to Q 2.12. If yes, record 
each hospitalization separately 
Yes = 01  
No = 00 
Doesn’t know = 88     
 
09a Date of first admission 




09c Date of second admission 




History of worm infestation   
10 Have you observed worms in your 
child’s stools 
Yes = 01  
No = 00 
Doesn’t know = 88     
 
11 Has your child been treated for worm 
infestations in the last 6 months? 
Yes = 01  
No = 00 
Doesn’t know = 88     
 
12 If yes, what is the medication taken? 
(ask for empty syrup bottle/ 
prescription for medicine details) 
 
13 Is your child on regular deworming 
medication? 
Yes = 01  
No = 00 





Does child have 
symptom today? 
a 
If yes, how 






Has child had 




If yes, how 
many episodes 




Has child had 
symptom in past 
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3 and 6-month Follow-up Version 1.0 




      
 
02 Todayʼs date (DD/MMM/YY)    /   /   
 
03 Current weight (kg)    .   
 
04 Current length (cm) 
     .   
 
05 Current head circumference (cm) 
     .   
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